E. Rizova

979 total citations
17 papers, 340 citations indexed

About

E. Rizova is a scholar working on Dermatology, Immunology and Allergy and Physiology. According to data from OpenAlex, E. Rizova has authored 17 papers receiving a total of 340 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Dermatology, 10 papers in Immunology and Allergy and 8 papers in Physiology. Recurrent topics in E. Rizova's work include Dermatology and Skin Diseases (15 papers), Asthma and respiratory diseases (8 papers) and Allergic Rhinitis and Sensitization (8 papers). E. Rizova is often cited by papers focused on Dermatology and Skin Diseases (15 papers), Asthma and respiratory diseases (8 papers) and Allergic Rhinitis and Sensitization (8 papers). E. Rizova collaborates with scholars based in United States, France and Netherlands. E. Rizova's co-authors include Albert M. Kligman, Marius Ardeleanu, Gianluca Pirozzi, Ana B. Rossi, Thomas Hultsch, Z. Chen, Yuan Lü, Neil M.H. Graham, Eric L. Simpson and Andreas Wollenberg and has published in prestigious journals such as Journal of Investigative Dermatology, Journal of the American Academy of Dermatology and British Journal of Dermatology.

In The Last Decade

E. Rizova

16 papers receiving 334 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
E. Rizova United States 11 282 180 102 55 51 17 340
Marlene Seegräber Germany 7 199 0.7× 140 0.8× 74 0.7× 34 0.6× 55 1.1× 14 257
Sophie Grande France 8 119 0.4× 74 0.4× 51 0.5× 87 1.6× 19 0.4× 10 230
Soo Jung Kim United States 5 492 1.7× 335 1.9× 179 1.8× 119 2.2× 93 1.8× 13 553
Shelbi Jim On United States 4 223 0.8× 147 0.8× 89 0.9× 80 1.5× 61 1.2× 4 274
Rachel Lefferdink United States 8 484 1.7× 361 2.0× 190 1.9× 100 1.8× 65 1.3× 15 557
Usman Chaudhry United States 5 429 1.5× 307 1.7× 200 2.0× 118 2.1× 90 1.8× 7 504
Talia Canter United States 6 446 1.6× 347 1.9× 187 1.8× 94 1.7× 65 1.3× 8 503
Irena Krčmová Czechia 11 102 0.4× 157 0.9× 135 1.3× 81 1.5× 25 0.5× 41 363
Xiaochun Liu China 11 219 0.8× 111 0.6× 78 0.8× 90 1.6× 57 1.1× 17 364
Khalad Maliyar Canada 9 185 0.7× 53 0.3× 51 0.5× 101 1.8× 39 0.8× 62 286

Countries citing papers authored by E. Rizova

Since Specialization
Citations

This map shows the geographic impact of E. Rizova's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E. Rizova with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E. Rizova more than expected).

Fields of papers citing papers by E. Rizova

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by E. Rizova. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E. Rizova. The network helps show where E. Rizova may publish in the future.

Co-authorship network of co-authors of E. Rizova

This figure shows the co-authorship network connecting the top 25 collaborators of E. Rizova. A scholar is included among the top collaborators of E. Rizova based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with E. Rizova. E. Rizova is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Paller, Amy S., Emma Guttman‐Yassky, Marie L. A. Schuttelaar, et al.. (2022). Disease characteristics, comorbidities, treatment patterns and quality of life impact in children <12 years old with atopic dermatitis: Interim results from the PEDISTAD Real-World Registry. Journal of the American Academy of Dermatology. 87(5). 1104–1108. 10 indexed citations
2.
3.
Bruin‐Weller, Marjolein de, Andrew Pink, Ana M. Giménez‐Arnau, et al.. (2021). Disease burden and treatment history among adults with atopic dermatitis receiving systemic therapy: baseline characteristics of participants on the EUROSTAD prospective observational study. Journal of Dermatological Treatment. 32(2). 164–173. 19 indexed citations
4.
Paller, Amy S., Emma Guttman‐Yassky, Alan D. Irvine, et al.. (2020). Protocol for a prospective, observational, longitudinal study in paediatric patients with moderate-to-severe atopic dermatitis (PEDISTAD): study objectives, design and methodology. BMJ Open. 10(3). e033507–e033507. 8 indexed citations
5.
Boralévi, F., Christine Bodemer, S. Mallet, et al.. (2020). Le fardeau de la dermatite atopique modérée à sévère chez les enfants de moins de12 ans : résultats de l’étude observationnelle PEDISTAD. Annales de Dermatologie et de Vénéréologie. 147(12). A363–A364.
6.
Wollenberg, Andreas, Andrew Blauvelt, Eric L. Simpson, et al.. (2020). Assessing the need for routine safety testing for patients being treated with dupilumab for moderate‐to‐severe atopic dermatitis. British Journal of Dermatology. 182(6). e186–e209. 3 indexed citations
7.
Ariëns, Lieneke F.M., Abhijit Gadkari, Harmieke van Os‐Medendorp, et al.. (2019). Dupilumab Versus Cyclosporine for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults: Indirect Comparison Using the Eczema Area and Severity Index. Acta Dermato Venereologica. 99(10). 851–857. 14 indexed citations
8.
Wollenberg, Andreas, Lisa A. Beck, Andrew Blauvelt, et al.. (2019). Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS). British Journal of Dermatology. 182(5). 1120–1135. 91 indexed citations
9.
10.
Bruin‐Weller, Marjolein de, Andrew Pink, Annalisa Patrizi, et al.. (2019). 161 EUROSTAD Prospective Observational Study: Baseline Characteristics, Atopic Dermatitis Severity, and Patient-Reported Outcomes. Journal of Investigative Dermatology. 139(9). S241–S241. 1 indexed citations
11.
Katoh, Norito, Hidehisa Saeki, Yoko Kataoka, et al.. (2019). Atopic dermatitis disease registry in Japanese adult patients with moderate to severe atopic dermatitis (ADDRESS‐J): Baseline characteristics, treatment history and disease burden. The Journal of Dermatology. 46(4). 290–300. 26 indexed citations
12.
Hamilton, Jennifer D., Sara Hamon, Eric L. Simpson, et al.. (2016). 372 The effect of dupilumab on biomarkers in a randomized phase 2b clinical trial in adults with moderate-to-severe atopic dermatitis. Journal of Investigative Dermatology. 136(9). S224–S224. 6 indexed citations
13.
Barker, Juliet N., et al.. (2003). Calcium homeostasis remains unaffected after 12 weeks' therapy with calcitriol 3 µg/g ointment; no correlation with extent of psoriasis. Journal of Dermatological Treatment. 14(1). 14–21. 13 indexed citations
14.
Rizova, E., et al.. (2001). Topical calcitriol - studies on local tolerance and systemic safety. British Journal of Dermatology. 144(s58). 3–10. 25 indexed citations
15.
Rizova, E. & Albert M. Kligman. (2001). New photographic techniques for clinical evaluation of acne. Journal of the European Academy of Dermatology and Venereology. 15(Suppl.3). 13–18. 35 indexed citations
16.
Rizova, E. & Albert M. Kligman. (2001). New photographic techniques for clinical evaluation of acne. Journal of the European Academy of Dermatology and Venereology. 15(s3). 13–18. 31 indexed citations
17.
Queille‐Roussel, Catherine, L. Duteil, Anne Parneix‐Spake, Stéphanie Arsonnaud, & E. Rizova. (2001). The safety of calcitriol 3 microg/g ointment. Evaluation of cutaneous contact sensitization, cumulative irritancy, photoallergic contact sensitization and phototoxicity.. PubMed. 11(3). 219–24. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Marlene Seegräber Breakdown of academic impact, for papers by Sophie Grande Breakdown of academic impact, for papers by Soo Jung Kim Breakdown of academic impact, for papers by Shelbi Jim On Breakdown of academic impact, for papers by Rachel Lefferdink Breakdown of academic impact, for papers by Usman Chaudhry Breakdown of academic impact, for papers by Talia Canter Breakdown of academic impact, for papers by Irena Krčmová Breakdown of academic impact, for papers by Xiaochun Liu Breakdown of academic impact, for papers by Khalad Maliyar
Rankless by CCL
2026